Methodology Report
Employment of Oligodeoxynucleotide plus Interleukin-2 Improves Cytogenetic Analysis in Splenic Marginal Zone Lymphoma
Table 1
Clinical features at presentation in 18 cases of SMZL.
| Median age, y (range) | 74 (56–85) | Sex, male/female | 13/5 | Splenomegaly yes/no | 11/7 | Lymphadenopathy (yes/no) | 1/14 | >40% lymphs in the BM aspirate | 11/4 | Lymphocytosis ≥5 × 109/L yes/no | 11/7 | Absolute lymphocyte count (×109/L) | 0.68–31.49 (median 6,63) | Villous lymphocytes yes/no | 6/9 | Hb < 12 g/dL yes/no | 5/13 (8.6–15.2) | Platelet count ≤100 × 109/L yes/no | 4/14 (52–239) | CD5 expression yes/no | 5/13 |
|
|